MENU

Detection of mutations from liquid biopsies - applications in cancer diagnostics

Speaker
  • Senior Development Scientist - Genomics and Cellular Research, Cytiva
    Biography

      Monika Seidel is the scientific lead on new product development from conception throughout feasibility to manufacturing handover. She has extensive knowledge of liquid biopsy-based diagnostic applications including explain ddPCR (ddPCR) and NGS and expertise in molecular biology, biochemistry, immunology-related techniques, mass spectrometry and stem cell biology. Monika's research has focused on dissecting molecular mechanisms of human diseases in the field of genomics, proteomics and lipidomics including explain iPSc based(iPSc) modelling of motor neuron degeneration, structure function relationship studies in Ryanodine Receptor 2 associated with sudden cardiac death and siRNA-based high content and high throughput screening for identification of molecular targets and signaling pathways of anti-cancer drugs. She has an M.Sc. degree in Biotechnology, B.Sc. in Organic Chemistry and holds a PhD in Medical Sciences from the University of Cardiff, UK.


    Abstract

    Cell-free DNA (cfDNA) is currently trending as a biomarker from liquid biopsy in several clinical applications, including oncology, organ and transplant medicine, and non-invasive prenatal testing (NIPT). Although considerably less invasive than tissue biopsy, due to the small amount of cfDNA found in circulation, there is a need to use efficient, highly sensitive extraction protocols coupled with robust and reliable technologies, such as next-generation sequencing (NGS) to detect these mutations.

    Join our webinar hosted by Monika Seidel (PhD) to discuss the results of a study using Cytiva’s magnetic silica bead-based Sera-Xtracta™ Cell-Free DNA extraction kit* and targeted NGS for cancer biomarker detection in advanced non-small cell lung cancer (NSCLC) patient samples. The study demonstrates performance in a clinically relevant scenario where patient samples are analyzed for therapy stratification.

    Learning objectives

    • Discuss the opportunities and challenges created with liquid biopsy samples
    • Review the impact of cell-free DNA extraction efficiency, yield and purity in downstream applications such as next-generation sequencing 
    • Demonstrate performance of Sera-Xtracta Cell-Free DNA Kit in a clinically relevant scenario where patient samples are analyzed for therapy stratification

    Show Resources
    Show Resources